Top-News
Montag,
11.05.2020 16:35
von
PR Newswire
| Aufrufe: 199
HBK Investments LP - Form 8.3 - Allergan Plc
Das Bild eines Finanzcharts (Symbolbild).
© deepblue4you / E+ / Getty Images
PR Newswire
London, May 11
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
- KEY INFORMATION
| Name of person dealing (Note 1) | HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds |
| Company dealt in | ALLERGAN PLC |
| Class of relevant security to which the dealings being disclosed relate (Note 2) | US $0.0001 Ordinary Shares |
| Date of dealing | 08 May 2020 |
- INTERESTS AND SHORT POSITIONS
- Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | |||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | 302,959 (0.09%) | |||||
| (2) Derivatives (other than options) | 8,600,000 (2.61%) | |||||
| (3) Options and agreements to purchase/sell | ||||||
| Total | 8,902,959 (2.70%) | |||||
- Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
| Class of relevant security: | Long | Short | ||||
| Number | (%) | Number | (%) | |||
| (1) Relevant securities | ||||||
| (2) Derivatives (other than options) | ||||||
| (3) Options and agreements to purchase/sell | ||||||
| Total | ||||||
Ap20
- DEALINGS (Note 4)
- Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit (Note 5) |
| Purchase | 200,000 | USD 192.1500 |
| Purchase | 2,859 | USD 192.0173 |
| Purchase | 100,000 | USD 192.2115 |
- Derivatives transactions (other than options transactions)
| Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
- Options transactions in respect of existing relevant securities
- Writing, selling, purchasing or varying
| Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
- Exercising
| Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
- Other dealings (including transactions in respect of new securities) (Note 4)
| Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
Ap21
2.OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) No.
| Date of disclosure | 11 May 2020 |
| Contact name | Jonathan Brown |
| Telephone number | +44 (0)20 7659 1906 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection (Note 10) |
Werbung
Mehr Nachrichten zur Allergan Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
